Pharmacogenomics of warfarin in populations of African descent

Decreased Warfarin Clearance Associated With the CYP2C9 R150H (*8) Polymorphism

(2012) Y Liu et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Predicting warfarin dosage in European–Americans and African–Americans using DNA samples linked to an electronic health record

(2012) Andrea H Ramirez et al.   PHARMACOGENOMICS

High-dimensional pharmacogenetic prediction of a continuous trait using machine learning techniques with application to warfarin dose prediction in African Americans

(2011) Erdal Cosgun et al.   BIOINFORMATICS

Population diversity and the performance of warfarin dosing algorithms

(2011) Guilherme Suarez-Kurtz   BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

EPHX1 Polymorphisms Are Not Associated With Warfarin Response in an Italian Population

(2011) C Ciccacci et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

The Missing Association: Sequencing-Based Discovery of Novel SNPs in VKORC1 and CYP2C9 That Affect Warfarin Dose in African Americans

(2011) M A Perera et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Evaluation of the effects of VKORC1 polymorphisms and haplotypes, CYP2C9 genotypes, and clinical factors on warfarin response in Sudanese patients

(2011) Nassr Eldin M. A. Shrif et al.   EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY

Acenocoumarol sensitivity and pharmacokinetic characterization of CYP2C9 *5/*8,*8/*11,*9/*11 and VKORC1*2 in black African healthy Beninese subjects

(2011) Aurel Constant Allabi et al.   EUROPEAN JOURNAL OF DRUG METABOLISM AND PHARMACOKINETICS

Genetic and nongenetic factors associated with warfarin doserequirements in Egyptian patients

(2011) Mohamed Hossam A. Shahin et al.   Pharmacogenetics and Genomics

Association of the GGCX (CAA)16/17 repeat polymorphism with higher warfarin dose requirements in African Americans

(2011) Larisa H. Cavallari et al.   Pharmacogenetics and Genomics

Letter to the Editor: Combined CYP2C9, VKORC1 and CYP4F2 frequencies among Amerindians, Mozambicans and Brazilians

(2011) Daniela D Vargens et al.   PHARMACOGENOMICS

Novel CYP2C9 and VKORC1 gene variants associated with warfarin dosage variability in the South African black population

(2011) Cathrine Mitchell et al.   PHARMACOGENOMICS

Genetic variants inCYP(-1A2,-2C9,-2C19,-3A4and-3A5),VKORC1andABCB1genes in a black South African population: a window into diversity

(2011) Collet Dandara et al.   PHARMACOGENOMICS

Association of Apolipoprotein E Genotype with Duration of Time to Achieve a Stable Warfarin Dose in African-American Patients

(2011) Larisa H Cavallari et al.   PHARMACOTHERAPY

The Genomic Ancestry of Individuals from Different Geographical Regions of Brazil Is More Uniform Than Expected

(2011) Sérgio D. J. Pena et al.   PLoS One

Warfarin pharmacogenetics: a single VKORC1 polymorphism is predictive of dose across 3 racial groups

(2010) N. A. Limdi et al.   BLOOD

Pharmacogenomics of Warfarin dose requirements in Hispanics☆

(2010) Larisa H. Cavallari et al.   BLOOD CELLS MOLECULES AND DISEASES

New genetic variant that might improve warfarin dose prediction in African Americans

(2010) Hedi Schelleman et al.   BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

A Polymorphism in the VKORC1 Regulator Calumenin Predicts Higher Warfarin Dose Requirements in African Americans

(2010) D Voora et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Impact of CYP4F2 rs2108622 on the Stable Warfarin Dose in an Admixed Patient Cohort

(2010) J A Perini et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Genetic and Clinical Predictors of Warfarin Dose Requirements in African Americans

(2010) L H Cavallari et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

VKORC1polymorphisms in Brazilians: comparison with the Portuguese and Portuguese-speaking Africans and pharmacogenetic implications

(2010) Guilherme Suarez-Kurtz et al.   PHARMACOGENOMICS

CombinedCYP2C9,VKORC1andCYP4F2frequencies among racial and ethnic groups

(2010) Stuart A Scott et al.   PHARMACOGENOMICS

Global pharmacogenomics: Impact of population diversity on the distribution of polymorphisms in the CYP2C cluster among Brazilians

(2010) G Suarez-Kurtz et al.   PHARMACOGENOMICS JOURNAL

VKORC1 Common Variation and Bone Mineral Density in the Third National Health and Nutrition Examination Survey

(2010) Dana C. Crawford et al.   PLoS One

VKORC1 V66M mutation in African Brazilian patients resistant to oral anticoagulant therapy

(2010) Fernanda A. Orsi et al.   THROMBOSIS RESEARCH

Relative contribution of VKORC1, CYP2C9, and INR response to warfarin stable dose

(2009) G. Suarez-Kurtz et al.   BLOOD

Genetic Factors (VKORC1, CYP2C9, EPHX1, and CYP4F2) Are Predictor Variables for Warfarin Response in Very Elderly, Frail Inpatients

(2009) E Pautas et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Exploring warfarin pharmacogenomics with the extreme-discordant-phenotype methodology: impact of FVII polymorphisms on stable anticoagulation with warfarin

(2009) Mateus Fuchshuber-Moraes et al.   EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY

Estimation of the Warfarin Dose with Clinical and Pharmacogenetic Data

(2009)   NEW ENGLAND JOURNAL OF MEDICINE

CYP2C9*8is prevalent among African–Americans: implications for pharmacogenetic dosing

(2009) Stuart A Scott et al.   PHARMACOGENOMICS

Genome-wide patterns of population structure and admixture in West Africans and African Americans

(2009) K. Bryc et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

The Genetic Structure and History of Africans and African Americans

(2009) S. A. Tishkoff et al.   SCIENCE

A Genome-Wide Association Study Confirms VKORC1, CYP2C9, and CYP4F2 as Principal Genetic Determinants of Warfarin Dose

(2009) Fumihiko Takeuchi et al.   PLoS Genetics

VKORC1 Asp36Tyr warfarin resistance marker is common in Ethiopian individuals

(2008) E. Aklillu et al.   BLOOD

Regulatory polymorphism in vitamin K epoxide reductase complex subunit 1 (VKORC1) affects gene expression and warfarin dose requirement

(2008) D. Wang et al.   BLOOD

Use of Pharmacogenetic and Clinical Factors to Predict the Therapeutic Dose of Warfarin

(2008) BF Gage et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Pharmacogenetics of Warfarin: Development of a Dosing Algorithm for Brazilian Patients

(2008) JA Perini et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Dosing Algorithms to Predict Warfarin Maintenance Dose in Caucasians and African Americans

(2008) H Schelleman et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

VKORC1polymorphisms, haplotypes and haplotype groups on warfarin dose among African–Americans and European–Americans

(2008) Nita A Limdi et al.   PHARMACOGENOMICS

Dosing algorithm for warfarin using CYP2C9 and VKORC1 genotyping from a multi-ethnic population: comparison with other equations

(2008) Alan HB Wu et al.   PHARMACOGENOMICS

Influence ofCYP2C9andVKORC1on warfarin dose, anticoagulation attainment and maintenance among European–Americans and African–Americans

(2008) Nita A Limdi et al.   PHARMACOGENOMICS